Safety of tacrine: Clinical trials, treatment IND, and postmarketing experience

Alzheimer Disease and Associated Disorders

Volumn 12, Issue 2, 1998, Pages 93-101

  Gracon, Stephen I ^a   Knapp, Margaret J ^a   Berghoff, William G ^a   Pierce, Mark ^a   DeJong, Richard ^a   Lobbestael, Sandra J ^a   Symons, James ^a   Dombey, Stuart L ^a   Luscombe, Faye A ^a   Kraemer, Dale ^a  

^a PFIZER INC   (United States)

Author keywords

Alzheimer disease; Cholinesterase inhibitor; Cognex ; Safety; Tacrine

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLINESTERASE INHIBITOR; TACRINE;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; ATAXIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM; DIGESTIVE SYSTEM ULCER; DRUG SAFETY; DYSPEPSIA; FEMALE; FLATULENCE; FRACTURE; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEART INFARCTION; HUMAN; LIVER FUNCTION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CARCINOMA; RASH; SYNCOPE; THORAX PAIN; TREMOR; UNITED STATES; VOMITING; WEIGHT REDUCTION;

EID: 20244370995     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199806000-00007     Document Type: Article

References (54)

1. Ames DJ, Bhathal PS, Davies BM, Fraser JRE. Hepatotoxicity of tetrahydroaminoacridine. Lancet 1988;1:887.
2. Ames DJ, Bhathal PS, Davies BM, Fraser JRE, Gibson PR, Roberts S. Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine. Aust NZ J Med 1990;20:193-5.
3. Askmark H, Aquilonius SM, Gillberg PG, et al. Functional and pharmacokinetic studies of tetrahydroaminoacridine in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 1990;82:253-8.
4. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
5. Chandra V, Bharucha NE, Schoenberg BS. Conditions associated with Alzheimer's disease at death: case-control study. Neurology 1986;36: 209-11.
6. Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicenter trial. BMJ 1990;300:495-9.
7. COSTART: coding symbols for thesaurus of adverse reaction terms, 2nd ed. Washington, DC: Department of Health and Human Services, FDA, 1985.
8. COSTART: coding symbols for thesaurus of adverse reaction terms, 3rd ed. Washington, DC: Department of Health and Human Services, FDA, 1989.
9. Davies B, Andrewes D, Stargatt R, Ames D, Tuckwell V, Davis S. Tacrine in Alzheimer's disease. Lancet 1989;2:163-4.
10. Davies B, Andrewes D, Stargatt R, Ames D, Tuckwell V, Davis S. Tetrahydroaminoacridine in Alzheimer's disease. Int J Geriatr Psychiatry 1990;5:317-21.
11. deVries TM, O'Connor-Semmes RL, Guttendorf RJ, et al. Effect of cimetidine and low-dose quinidine on tacrine pharmacokinetics in humans [abstract PPDM 815]. Pharm Res 1993a;10(suppl):S337.
12. deVries TM, Siedlik P, Smithers JA, et al. Effect of multiple-dose tacrine administration on single-dose pharmacokinetics of digoxin, diazepam, and theophylline [abstract PPDM 813]. Pharm Res 1993b;10(suppl):S333.
13. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-9.
14. Fitten LJ, Steinberg A, Fine H, Perryman K, Tymon M. THA treatment of Alzheimer's disease: toxicology in a double-blind, placebo-controlled, inpatient trial [abstract A25]. J Am Geriatr Soc 1988;36:581.
15. Fitten LJ, Ferryman K, Gross PL, Fine H, Cummins J, Marshall C. Treatment of Alzheimer's disease with short-and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry 1990;147:239-42.
16. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975;12:189-98.
17. Forsyth DR, Surmon DJ, Morgan RA, Wilcock GK. Clinical experience with and side effects of tacrine hydrochloride in Alzheimer's disease: a pilot study. Age Ageing 1989;18:223-9.
18. Gauthier S, Masson H, Gauthier L, et al. Tetrahydroaminoacridine and lecithin in Alzheimer's disease. In: Giacobini E, Becker R, eds. Current research in Alzheimer's therapy. New York: Taylor and Francis, 1988:237-45.
19. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroammoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl J Med, 1990;322:1272-6.
20. Gibson PR, Bhathal PS, Ames DJ, Roberts SK, Davies B, Fraser JRE. Heterogeneity of hepatic adverse reactions to tetrahydroaminoacridine (THA) [abstract 705]. Hepatology 1989;10:745.
21. Gordh T, Wahlin A. Potentiation of the neuromuscular effect of succinylcholine by tetrahydro-amino-acridine. Acta Anaesthesiol Scand 1961;5:55-61.
22. Hammel P, Larrey D, Bernuau J, et al. Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. J Clin Gastroenterol 1990;12:329-31.
23. Itil T, Fink M. EEG and behavioral aspects of the interaction of anticholinergic hallucinogens with centrally active compounds. Prog Brain Res 1968;28:149-68.
24. Jick H. Drug-associated asymptomatic elevations of transaminase in drug safety assessments. Pharmacotherapy 1995;15:23-5.
25. Kaye WH, Sitaram N, Weingartner H, Ebert MH, Smallberg S, Gillin JC. Modest facilitation of memory in dementia with combined lecithin and anticholinesterase treatment. Biol Psychiatry 1982;17:275-80.
26. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
27. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex®) treatment: effects on nursing home placement and mortality. Neurology 1996;47:165-77.
28. Kukull WA, Brenner DE, Speck CE, et al. Causes of death associated with Alzheimer disease: variation by level of cognitive impairment before death. J Am Geriatr Soc 1994;42:723-6.
29. Le Pensec D, Braguer D, Crevat A, Habib H, Khalil R. Therapeutic trial of tetrahydroaminoacridine in Alzheimer's disease. J Pharm Clin 1988; 7:121-30.
30. Maltby N, Creasey H, Broe GA, Concord RGH. Tetrahydroaminoacridine (THA) in Alzheimer's disease (AD). Aust NZ J Med 1990;20:382.
31. Marx JL. Alzheimer's drug trial put on hold. Science 1987;238:1041-2.
32. McSwain ML, Forman LM. Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol. J Clin Psychopharmacol 1995;15:284.
33. Minthon L, Dalfelt G, Gustafson L, Hagberg B, Rosen I, Risberg J. Oral tetrahydroaminoacridine and lecithin treatment for Alzheimer's disease [abstract 390]. Neurobiol Aging 1990;11:348.
34. Molloy DW, Guyatt GH, Wilson DB, Duke R, Rees L, Singer J. Effects of tetrahydroaminoacridine on cognition, function, and behaviour in Alzheimer's disease. Can Med Assoc J 1991;144:29-34.
35. Molsa PK, Marttila RJ, Rinne UK. Survival and cause of death in Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand 1986;74:103-7.
36. Nyback H, Ahlin A, Gustafson L, Minthon L. Swedish experiences of THA therapy in Alzheimer's disease. In: Becker R, Giacobini E, eds. Cholinergic basis for Alzheimer therapy. Cambridge: Birkhauser Boston 1991:216-23.
37. Nyback H, Nyman H, Ohman G, Nordgren I, Lindstrom B. Preliminary experiences and results with THA for the amelioration of symptoms of Alzheimer's disease. In: Giacobini E, Becker R, eds. Current research in Alzheimer's therapy. New York: Taylor and Francis, 1988:231-6.
38. Ott BR, Lannon MC. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol 1992;15:322-5.
39. Otton SV, Dafang W, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
40. Risse SC, Lampe TH, Bird TD, et al. Myoclonus, seizures, and paratonia in Alzheimer disease. Alzheimer Dis Assoc Disord 1990;4:217-25.
41. Roberts SK, Gibson PR, Bhathal PS, Ames DJ, Davies B, Fraser JRE. Heterogeneity of hepatic adverse reactions to tetrahydroaminoacridine. Aust NZ J Med 1990;20(suppl 1):361.
42. SAS Institute, Inc. SAS user's guide: statistics, 5th ed. Cary, North Carolina: SAS Institute Inc, 1985.
43. Summers WK, Veisselman JO, Marsh GM, Candelora K. Use of THA in treatment of Alzheimer'-like dementia: pilot study in twelve patients. Biol Psychiatry 1981;16:145-153.
44. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-5.
45. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Tacrine, back to the future? In: Giacobini E, Becker R, eds. Current research in Alzheimer therapy. New York: Taylor and Francis, 1988:259-65.
46. Summers WK, Koehler AL, Marsh GM, Tachiki K, Kling A. Long-term hepatotoxicity of tacrine. Lancet 1989a;1:729.
47. Summers WK, Tachiki K, Kling A. Tacrine in the treatment of Alzheimer's disease. A clinical update and recent pharmacologic studies. Eur Neurol 19896;29(suppl 3):28-32.
48. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701-7.
49. Title 21, Code of Federal Regulations, Section 314, revised. April 1, 1994:82.
50. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-20.
51. Watkins PB. Role of cytochrome P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 1990;10:235-50.
52. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
53. Weinstein HC, Teunisse S, van Gool WA. Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer's disease. J Neurol 1991;238:34-8.
54. Wilcock GK, Surmon D, Forsyth D, Morgan R. Cholinergic side effects of tetrahydroaminoacridine. Lancet 1988;2:1305.